Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).

Full DD Report for RCKT

You must become a subscriber to view this report.


Recent News from (NASDAQ: RCKT)

Gene therapy players under pressure
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: September, 05 2018 10:58
Rocket Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that members of Rocket’s executive team will participate in the following upcoming investor conferences: Citi’s 13 th Annual ...
Source: Business Wire
Date: August, 30 2018 07:00
FDA and NIH to loosen oversight of gene therapy development
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study...
Source: SeekingAlpha
Date: August, 16 2018 09:47
Rocket Pharmaceuticals misses by $0.03
Rocket Pharmaceuticals (NASDAQ: RCKT ): Q2 EPS of -$0.40 misses by $0.03 . More news on: Rocket Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 08 2018 07:11
Rocket Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
- Achieved Regulatory Designations for Fanconi Anemia (FA) in the U.S. and Europe; Registrational Trial on Track for 2019 - - Presented Promising Fanconi Anemia Data at ASGCT - - Adeno-associated Viral Vector Program Disclosure on Track for Fourth Quarter of 2018 - Rocket...
Source: Business Wire
Date: August, 08 2018 07:00
European Court makes restrictive ruling on genome editing
The European Union's Court of Justice has ruled that genetically edited organisms (via a process called mutagenesis) will now be subject to EU GMO law, previously restricted to organisms derived through transgenesis (insertion of DNA from one species into another). More news on: Health C...
Source: SeekingAlpha
Date: July, 30 2018 08:05
Upcoming 3% To 4% Book Value Growth For This 9.2% Yielding BDC Positioned For Rising Rates
Q2 2018 BDC Reporting Business development companies ("BDCs") will be reporting June 30, 2018, results this weeks including Hercules Capital ( HTGC ) and I will likely be making changes to my personal portfolio. My recent articles on THL Credit ( TCRD ), Ares Capital ( ARCC ), and M...
Source: SeekingAlpha
Date: July, 29 2018 10:32
Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, announced that the Company will join the broad-market Russell 3000 ® and Russell 2000 ® Indexes. The newly reconstituted indexes take effect after the...
Source: Business Wire
Date: June, 22 2018 07:00
Gene therapy players in the green
Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo...
Source: SeekingAlpha
Date: June, 20 2018 14:27
Institutional Top Ideas: Cormorant Asset Management
In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t...
Source: SeekingAlpha
Date: June, 16 2018 18:41

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0823.2523.1523.7522.77199,109
2018-05-1721.9719.9322.403619.61866,810

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1175,996167,96345.2457Short
2018-12-1032,15694,46334.0408Cover
2018-12-0724,90592,91826.8032Cover
2018-12-0617,55060,30629.1016Cover
2018-12-0424,81873,31933.8493Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RCKT.


About Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)

Logo for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $708,054,353 - 05/11/2018
  • Issue and Outstanding: 39,402,023 - 03/01/2018

 


Recent Filings from (NASDAQ: RCKT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 07 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: RCKT)

Daily Technical Chart for (NASDAQ: RCKT)


Stay tuned for daily updates and more on (NASDAQ: RCKT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RCKT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RCKT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RCKT and does not buy, sell, or trade any shares of RCKT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/